Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indonesia Rule To Make Foreign Drug Firms Have Local Plant Under Fire

This article was originally published in PharmAsia News

Executive Summary

Indonesia's government is taking a look at a proposed regulation to require foreign drug makers to have a manufacturing plant before they can enter the nation's market. The review is in response to assertions by foreign diplomats who say the regulation could be a violation of World Trade Organization rules. The proposed regulation is one of several actions the Indonesian government has taken in response to the global financial crisis. The head of Indonesia FDA said the government would be flexible in implementing the rule and that it would be applied on a case-by-case basis and unlikely to be enforced 100 percent unless in tandem with increasing the capacity of the domestic industry. But diplomats said such discrimination also could violate WTO rules. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel